Liminatus Pharma, Inc. - Class A Common Stock

Liminatus Pharma, Inc. - Class A Common Stock Share · US53271X1081 · LIMN (XNAS) — real-time quotes, company data, dividends, fundamentals, and AI-powered portfolio analysis on MoneyPeak

Overview
AI-Powered Analysis
Fundamental Analysis
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of Liminatus Pharma, Inc. - Class A Common Stock
No Price
01.05.2026 23:41
Current Prices from Liminatus Pharma, Inc. - Class A Common Stock
ExchangeTickerCurrencyLast TradePriceDaily Change
XNAS: NASDAQ
NASDAQ
LIMN
USD
01.05.2026 23:41
0,21 USD
0,005 USD
+2,45 %
IEXG: IEX
IEX
LIMN
USD
01.05.2026 19:58
0,21 USD
0,003 USD
+1,42 %
Share Float & Liquidity
Free Float 30,09 %
Shares Float 8,07 M
Shares Outstanding 26,83 M
Company Profile for Liminatus Pharma, Inc. - Class A Common Stock Share
Liminatus Pharma, Inc. operates as a clinical-stage immuno-oncology company that develops novel cancer therapies. The company is based in LA Palma, California.

Company Data

Name Liminatus Pharma, Inc. - Class A Common Stock
Company Liminatus Pharma, Inc. Class A Common Stock
Symbol LIMN
Website https://liminatuspharma.com
Primary Exchange XNAS NASDAQ
ISIN US53271X1081
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Chris Kim
Country United States of America
Currency USD
Employees 0,0 T
Address 6 Centerpointe Drive, 90623 La Palma
IPO Date 2025-05-01

Ticker Symbols

Name Symbol
NASDAQ LIMN
More Shares
Investors who hold Liminatus Pharma, Inc. - Class A Common Stock also have the following shares in their portfolio:
OFFICE PPTYS 21/31
OFFICE PPTYS 21/31 Bond
PRO.EUR.FIN. 22/29
PRO.EUR.FIN. 22/29 Bond